Basis Drugs this week introduced a brand new partnership with Epic to combine its genomic profiling and testing companies into its digital well being system.
WHY IT MATTERS
Cambridge, Massachusetts-based Basis Drugs presents a collection of genomic profiling assays to establish the molecular alterations of sufferers’ cancers and match them with focused therapies and medical trials. With this new collaboration prospects will have the ability to electronically order Basis assessments throughout the Epic community, instantly throughout the EHR.
The collaboration is aimed toward oncology practices, hospitals, educational medical facilities and well being techniques, to allow quick access to medical and genomic data for extra streamlined medical resolution help.
With the brand new integration, medical groups can place orders for Basis’s complete genomic profiling assessments – and obtain and think about outcomes – inside their present EHR workflow. The purpose is to additionally scale back information entry whereas providing quicker actionable insights to assist physicians information remedy planning.
The mixing is anticipated to be obtainable in 2022. Basis Drugs says it’s also partnering with organizations utilizing non-Epic EHRs to satisfy their very own oncology wants.
THE LARGER TREND
This is not the one information this week about genomics-focused precision resolution help. On Wednesday, AccessDX Holdings, developer of lab diagnostics and CDS instruments, introduced its acquisition of 2bPrecise – which helps well being techniques advance precision medication by aggregating genomics from labs and medical data from EHRs – from Allscripts.
Earlier this month, in an interview with Healthcare IT Information at HIMSS21, Dr. Robert Bart, chief medical data officer at Pittsburgh-based UPMC, highlighted the need of digitized discrete information, built-in into EHR workflows, for precision medication to work.
“We actually suppose that, if you’re shifting into the world of pharmacogenomics or genomic medication, that you really want to embed resolution help into your digital well being document,” he stated.Â
“And you must actually insist on taking the outcomes solely in digital format. So if we get exterior outcomes from reference labs, we do not need PDFs. We wish to truly discrete information, so we will set off the choice help, in addition to present supporting content material for interpretation by our clinicians – and the content material so the affected person can perceive what that consequence means for them.”
ON THE RECORD
“With a view to deliver the fact of precision medication to extra most cancers sufferers, we have to simplify the method for getting oncologists entry to the genomic insights they want for focused remedy planning,” stated Kathleen Kaa, interim chief business officer at Basis Drugs, in an announcement concerning the new Epic integrations.
She referred to as it “considered one of our key efforts to enhance the method for ordering our assessments so care groups can deal with offering the perfect remedy for his or her sufferers.”
Twitter:Â @MikeMiliardHITN
Electronic mail the author:Â mike.miliard@himssmedia.com
Healthcare IT Information is a HIMSS publication.
